151 related articles for article (PubMed ID: 38002777)
1. Biomarkers for Monitoring of Changes in Disease Activity in Ulcerative Colitis.
Tatsumi Y; Kakimoto K; Hara A; Mizuta N; Numa K; Kinoshita N; Nakazawa K; Koshiba R; Hirata Y; Ota K; Miyazaki T; Nakamura S; Sakagami K; Arimitsu S; Ito H; Nishikawa H
J Clin Med; 2023 Nov; 12(22):. PubMed ID: 38002777
[TBL] [Abstract][Full Text] [Related]
2. Leucine-Rich Alpha-2 Glycoprotein Is a Reliable Serum Biomarker for Evaluating Clinical and Endoscopic Disease Activity in Inflammatory Bowel Disease.
Shimoyama T; Yamamoto T; Yoshiyama S; Nishikawa R; Umegae S
Inflamm Bowel Dis; 2023 Sep; 29(9):1399-1408. PubMed ID: 36334015
[TBL] [Abstract][Full Text] [Related]
3. Early change in serum leucine-rich α-2-glycoprotein predicts clinical and endoscopic response in ulcerative colitis.
Karashima R; Sagami S; Yamana Y; Maeda M; Hojo A; Miyatani Y; Nakano M; Matsuda T; Hibi T; Kobayashi T
Intest Res; 2024 Jun; ():. PubMed ID: 38835140
[TBL] [Abstract][Full Text] [Related]
4. Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis.
Serada S; Fujimoto M; Terabe F; Iijima H; Shinzaki S; Matsuzaki S; Ohkawara T; Nezu R; Nakajima S; Kobayashi T; Plevy SE; Takehara T; Naka T
Inflamm Bowel Dis; 2012 Nov; 18(11):2169-79. PubMed ID: 22374925
[TBL] [Abstract][Full Text] [Related]
5. Appropriate leucine-rich α-2 glycoprotein cut-off value for Japanese patients with ulcerative colitis.
Yamazato M; Yanai S; Oizumi T; Eizuka M; Yamada S; Toya Y; Uesugi N; Sugai T; Matsumoto T
World J Clin Cases; 2023 Nov; 11(32):7753-7760. PubMed ID: 38073694
[TBL] [Abstract][Full Text] [Related]
6. Leucine-Rich Alpha-2 Glycoprotein in Monitoring Disease Activity and Intestinal Stenosis in Inflammatory Bowel Disease.
Yoshida T; Shimodaira Y; Fukuda S; Watanabe N; Koizumi S; Matsuhashi T; Onochi K; Iijima K
Tohoku J Exp Med; 2022 Jul; 257(4):301-308. PubMed ID: 35598974
[TBL] [Abstract][Full Text] [Related]
7. Novel Utility of Leucine-Rich Alpha-2-Glycoprotein as a Biomarker in Ulcerative Colitis: A Predictor of Endoscopic Remission Independent of Symptoms.
Hayashi T; Kitamura K; Usami M; Miyazawa M; Nishitani M; Dejima A; Yamamoto M; Kawase S; Funaki M; Orita N; Nakagawa H; Morita K; Iida N; Seki A; Nio K; Kido H; Takayama H; Takeuchi Y; Yamada S; Takatori H; Shimada M; Saito H; Yamamoto D; Toyama T; Yamashita T
Inflamm Intest Dis; 2023 Dec; 8(4):133-142. PubMed ID: 38115911
[TBL] [Abstract][Full Text] [Related]
8. Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study.
Shinzaki S; Matsuoka K; Tanaka H; Takeshima F; Kato S; Torisu T; Ohta Y; Watanabe K; Nakamura S; Yoshimura N; Kobayashi T; Shiotani A; Hirai F; Hiraoka S; Watanabe M; Matsuura M; Nishimoto S; Mizuno S; Iijima H; Takehara T; Naka T; Kanai T; Matsumoto T
J Gastroenterol; 2021 Jun; 56(6):560-569. PubMed ID: 33942166
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Serum Leucine-Rich Alpha-2 Glycoprotein as a New Inflammatory Biomarker of Inflammatory Bowel Disease.
Yoshimura T; Mitsuyama K; Sakemi R; Takedatsu H; Yoshioka S; Kuwaki K; Mori A; Fukunaga S; Araki T; Morita M; Tsuruta K; Yamasaki H; Torimura T
Mediators Inflamm; 2021; 2021():8825374. PubMed ID: 33623482
[TBL] [Abstract][Full Text] [Related]
10. Serum leucine-rich alpha-2 glycoprotein as a predictive factor of endoscopic remission in Crohn's disease.
Abe I; Shiga H; Chiba H; Miyazawa T; Oomori S; Shimoyama Y; Moroi R; Kuroha M; Kakuta Y; Kinouchi Y; Masamune A
J Gastroenterol Hepatol; 2022 Sep; 37(9):1741-1748. PubMed ID: 35641439
[TBL] [Abstract][Full Text] [Related]
11. Serum leucine-rich alpha-2 glycoprotein and calprotectin in children with inflammatory bowel disease: A multicenter study in Japan.
Yasuda R; Arai K; Kudo T; Nambu R; Aomatsu T; Abe N; Kakiuchi T; Hashimoto K; Sogo T; Takahashi M; Etani Y; Kato K; Yamashita Y; Mitsuyama K; Mizuochi T
J Gastroenterol Hepatol; 2023 Jul; 38(7):1131-1139. PubMed ID: 36880154
[TBL] [Abstract][Full Text] [Related]
12. Application of plasma alternative to serum for measuring leucine-rich α2-glycoprotein as a biomarker of inflammatory bowel disease.
Ichimiya T; Kazama T; Ishigami K; Yokoyama Y; Hayashi Y; Takahashi S; Itoi T; Nakase H
PLoS One; 2023; 18(6):e0286415. PubMed ID: 37352151
[TBL] [Abstract][Full Text] [Related]
13. Leucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis.
Shinzaki S; Matsuoka K; Iijima H; Mizuno S; Serada S; Fujimoto M; Arai N; Koyama N; Morii E; Watanabe M; Hibi T; Kanai T; Takehara T; Naka T
J Crohns Colitis; 2017 Jan; 11(1):84-91. PubMed ID: 27466171
[TBL] [Abstract][Full Text] [Related]
14. Leucine-rich alpha-2 glycoprotein as a marker of mucosal healing in inflammatory bowel disease.
Yasutomi E; Inokuchi T; Hiraoka S; Takei K; Igawa S; Yamamoto S; Ohmori M; Oka S; Yamasaki Y; Kinugasa H; Takahara M; Harada K; Furukawa M; Itoshima K; Okada K; Otsuka F; Tanaka T; Mitsuhashi T; Kato J; Okada H
Sci Rep; 2021 May; 11(1):11086. PubMed ID: 34045529
[TBL] [Abstract][Full Text] [Related]
15. Leucine-Rich Alpha-2 Glycoprotein May Be Predictive of the Adalimumab Trough Level and Antidrug Antibody Development for Patients with Inflammatory Bowel Disease: A Sub-Analysis of the PLANET Study.
Yanai S; Shinzaki S; Matsuoka K; Mizuno S; Iijima H; Naka T; Kanai T; Matsumoto T
Digestion; 2021; 102(6):929-937. PubMed ID: 34350873
[TBL] [Abstract][Full Text] [Related]
16. Serum Leucine-Rich α2 Glycoprotein: A Biomarker for Predicting the Presence of Ulcerative Colitis but Not Ulcerative Proctitis.
Horiuchi I; Horiuchi A; Umemura T
J Clin Med; 2022 Oct; 11(21):. PubMed ID: 36362594
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of the Optimal Cutoff Value and Delta Value of Leucine-Rich Alpha 2 Glycoprotein in Ulcerative Colitis.
Matsumoto S; Mashima H
Crohns Colitis 360; 2022 Oct; 4(4):otac039. PubMed ID: 36778513
[TBL] [Abstract][Full Text] [Related]
18. Serum leucine-rich alpha-2 glycoprotein in monitoring disease activity and intestinal mucosal healing for biotherapy-naïve cases with ulcerative colitis.
Kono M; Komeda Y; Tribonias G; Yoshida S; Nomura K; Handa K; Nagai T; Hagiwara S; Omoto S; Takenaka M; Nishida N; Tsuji N; Kashida H; Kudo M
JGH Open; 2023 Aug; 7(8):579-583. PubMed ID: 37649867
[TBL] [Abstract][Full Text] [Related]
19. Comparison of fecal calprotectin and serum C-reactive protein in early prediction of outcome to infliximab induction therapy.
Engström J; Lönnkvist M; Befrits R; Ljung T; Diaz-Tartera H; Holst M; Hellström PM
Scand J Gastroenterol; 2019 Sep; 54(9):1081-1088. PubMed ID: 31499013
[No Abstract] [Full Text] [Related]
20. Leucine-rich α2 -glycoprotein as a potential biomarker for joint inflammation during anti-interleukin-6 biologic therapy in rheumatoid arthritis.
Fujimoto M; Serada S; Suzuki K; Nishikawa A; Ogata A; Nanki T; Hattori K; Kohsaka H; Miyasaka N; Takeuchi T; Naka T
Arthritis Rheumatol; 2015 May; 67(8):2056-60. PubMed ID: 25917892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
